Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Nov 13;22(5):563-4.
doi: 10.1016/j.ccr.2012.10.011.

Metastatic ability: adapting to a tissue site unseen

Affiliations
Comment

Metastatic ability: adapting to a tissue site unseen

Neil A Bhowmick. Cancer Cell. .

Abstract

The microenvironment of the primary as well as the metastatic tumor sites can determine the ability for a disseminated tumor to progress. In this issue of Cancer Cell, Calon and colleagues find that systemic TGF-β can facilitate colon cancer metastatic engraftment and expansion.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Scenarios for metastatic expansion
There are multiple possible mechanisms for metastatic progression. We assume that the rate limiting steps of metastasis do not necessarily involve the processes of tumor cell dissemination, but rather compatibility of tumor cells with their metastatic site. A. A primary tumor cell can acquire traits within the primary tumor that enable its progression in the metastatic site. B. Alternatively, the disseminated tumor cells that lodge in the metastatic site can lie ‘dormant’ until the new microenvironment potentiates the acquisition of traits that enable tumor progression. C. The work by Calon et al. (2012) suggest that elevated TGF-β and its downstream products induce changes in the microenvironment of the primary tumor and the metastatic site to facilitate metastatic progression. There are other possibilities mediating metastatic progression including variations and combinations of these three scenarios. The role of the immune system is not accounted for in this assessment.

Comment on

References

    1. Blum DL, Koyama T, M’Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Jr, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008;14:7790–7797. - PMC - PubMed
    1. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99–111. - PubMed
    1. Calon, et al. (this issue)
    1. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A. 2008;105:4283–4288. - PMC - PubMed
    1. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–827. - PMC - PubMed

LinkOut - more resources